利拉鲁肽与西马鲁肽的体重减轻-治疗分析所需的成本

IF 4.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Obesity Pub Date : 2023-05-19 DOI:10.1002/oby.23752

Joseph Azuri, Ariel Hammerman, Enis Aboalhasan, Ben Sluckis, Ronen Arbel

{"title":"利拉鲁肽与西马鲁肽的体重减轻-治疗分析所需的成本","authors":"Joseph Azuri, Ariel Hammerman, Enis Aboalhasan, Ben Sluckis, Ronen Arbel","doi":"10.1002/oby.23752","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>Higher doses of the glucagon-like peptide-1 agonists liraglutide and, more recently, semaglutide have demonstrated a significant reduction in body weight. However, their comparative value for money for this indication is unclear.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The cost needed to treat to achieve a 1% reduction in body weight using semaglutide or liraglutide was calculated. The body weight reductions were extracted from the published STEP 1 trial and the SCALE trial results, respectively. A scenario analysis was performed to mitigate the primary differences between the two studies' populations. Drug costs were based on US GoodRx prices as of October 2022.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Liraglutide in STEP 1 resulted in a weight loss of 5.4% (95% CI: 5%-5.8%). Semaglutide in SCALE resulted in a weight loss of 12.4% (95% CI: 11.5%-13.4%). The total cost of therapy with liraglutide during the trial was estimated at $17,585 compared with $22,878 with semaglutide. Accordingly, the cost needed to treat per 1% of body weight reduction with liraglutide is estimated at $3256 (95% CI: $3032-$3517) compared with $1845 (95% CI: $1707-$1989) with semaglutide.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Semaglutide provides significantly better value for money than liraglutide for weight reduction.</p>\n </section>\n </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"31 6","pages":"1510-1513"},"PeriodicalIF":4.2000,"publicationDate":"2023-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.23752","citationCount":"3","resultStr":"{\"title\":\"Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis\",\"authors\":\"Joseph Azuri, Ariel Hammerman, Enis Aboalhasan, Ben Sluckis, Ronen Arbel\",\"doi\":\"10.1002/oby.23752\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>Higher doses of the glucagon-like peptide-1 agonists liraglutide and, more recently, semaglutide have demonstrated a significant reduction in body weight. However, their comparative value for money for this indication is unclear.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>The cost needed to treat to achieve a 1% reduction in body weight using semaglutide or liraglutide was calculated. The body weight reductions were extracted from the published STEP 1 trial and the SCALE trial results, respectively. A scenario analysis was performed to mitigate the primary differences between the two studies' populations. Drug costs were based on US GoodRx prices as of October 2022.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Liraglutide in STEP 1 resulted in a weight loss of 5.4% (95% CI: 5%-5.8%). Semaglutide in SCALE resulted in a weight loss of 12.4% (95% CI: 11.5%-13.4%). The total cost of therapy with liraglutide during the trial was estimated at $17,585 compared with $22,878 with semaglutide. Accordingly, the cost needed to treat per 1% of body weight reduction with liraglutide is estimated at $3256 (95% CI: $3032-$3517) compared with $1845 (95% CI: $1707-$1989) with semaglutide.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Semaglutide provides significantly better value for money than liraglutide for weight reduction.</p>\\n </section>\\n </div>\",\"PeriodicalId\":215,\"journal\":{\"name\":\"Obesity\",\"volume\":\"31 6\",\"pages\":\"1510-1513\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2023-05-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.23752\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obesity\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/oby.23752\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/oby.23752","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 3

摘要

目的:高剂量的胰高血糖素样肽-1激动剂利拉鲁肽和最近的西马鲁肽已被证明能显著减轻体重。然而，它们在这一指标上的相对价值尚不清楚。方法计算使用西马鲁肽或利拉鲁肽使体重减轻1%所需的治疗费用。体重减少分别从已发表的STEP 1试验和SCALE试验结果中提取。进行情景分析以减轻两项研究人群之间的主要差异。药品成本基于截至2022年10月的美国GoodRx价格。利拉鲁肽在第1步中导致体重减轻5.4% (95% CI: 5%-5.8%)。Semaglutide在SCALE中导致体重减轻12.4% (95% CI: 11.5%-13.4%)。试验期间利拉鲁肽治疗的总费用估计为17,585美元，而西马鲁肽治疗的总费用为22,878美元。因此，利拉鲁肽每减少1%体重所需的治疗费用估计为3256美元(95% CI: 3032- 3517美元)，而西马鲁肽为1845美元(95% CI: 1707- 1989美元)。结论西马鲁肽的减肥效果明显优于利拉鲁肽。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis

Objective

Higher doses of the glucagon-like peptide-1 agonists liraglutide and, more recently, semaglutide have demonstrated a significant reduction in body weight. However, their comparative value for money for this indication is unclear.

Methods

The cost needed to treat to achieve a 1% reduction in body weight using semaglutide or liraglutide was calculated. The body weight reductions were extracted from the published STEP 1 trial and the SCALE trial results, respectively. A scenario analysis was performed to mitigate the primary differences between the two studies' populations. Drug costs were based on US GoodRx prices as of October 2022.

Results

Liraglutide in STEP 1 resulted in a weight loss of 5.4% (95% CI: 5%-5.8%). Semaglutide in SCALE resulted in a weight loss of 12.4% (95% CI: 11.5%-13.4%). The total cost of therapy with liraglutide during the trial was estimated at $17,585 compared with $22,878 with semaglutide. Accordingly, the cost needed to treat per 1% of body weight reduction with liraglutide is estimated at $3256 (95% CI: $3032-$3517) compared with $1845 (95% CI: $1707-$1989) with semaglutide.

Conclusions

Semaglutide provides significantly better value for money than liraglutide for weight reduction.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Obesity 医学-内分泌学与代谢

CiteScore

11.70

自引率

1.40%

发文量

261

审稿时长

2-4 weeks

期刊介绍： Obesity is the official journal of The Obesity Society and is the premier source of information for increasing knowledge, fostering translational research from basic to population science, and promoting better treatment for people with obesity. Obesity publishes important peer-reviewed research and cutting-edge reviews, commentaries, and public health and medical developments.